Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology

被引:9
作者
Yu, Yunfeng [1 ,2 ]
Zhou, Manli [1 ]
Long, Xi [2 ]
Yin, Shuang [1 ]
Hu, Gang [2 ]
Yang, Xinyu [1 ]
Jian, Weixiong [1 ,3 ]
Yu, Rong [2 ]
机构
[1] Hunan Univ Chinese Med, Coll Chinese Med, Changsha, Hunan, Peoples R China
[2] Hunan Univ Chinese Med, Affiliated Hosp 1, Changsha, Hunan, Peoples R China
[3] Hunan Univ Chinese Med, Key Lab Chinese Med Diagnost Hunan Prov, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
colchicine; coronary artery disease; network pharmacology; molecular docking; mechanism of action; LOW-DOSE-COLCHICINE; CYTOCHROME-C; MYELOPEROXIDASE; ATHEROSCLEROSIS; MITOCHONDRIAL; INJURY; METAANALYSIS; PREVENTION; APOPTOSIS; ASPIRIN;
D O I
10.3389/fphar.2023.1147360
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This is the first study to explore the mechanism of colchicine in treating coronary artery disease using network pharmacology and molecular docking technology, aiming to predict the key targets and main approaches of colchicine in treating coronary artery disease. It is expected to provide new ideas for research on disease mechanism and drug development.Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Swiss Target Prediction and PharmMapper databases were used to obtain drug targets. GeneCards, Online Mendelian Inheritance in Man (OMIM), Therapeutic Target Database (TTD), DrugBank and DisGeNET databases were utilized to gain disease targets. The intersection of the two was taken to access the intersection targets of colchicine for the treatment of coronary artery disease. The Sting database was employed to analyze the protein-protein interaction network. Gene Ontology (GO) functional enrichment analysis was performed using Webgestalt database. Reactom database was applied for Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Molecular docking was simulated using AutoDock 4.2.6 and PyMOL2.4 software.Results: A total of 70 intersecting targets of colchicine for the treatment of coronary artery disease were obtained, and there were interactions among 50 targets. GO functional enrichment analysis yielded 13 biological processes, 18 cellular components and 16 molecular functions. 549 signaling pathways were obtained by KEGG enrichment analysis. The molecular docking results of key targets were generally good.Conclusion: Colchicine may treat coronary artery disease through targets such as Cytochrome c (CYCS), Myeloperoxidase (MPO) and Histone deacetylase 1 (HDAC1). The mechanism of action may be related to the cellular response to chemical stimulus and p75NTR-mediated negative regulation of cell cycle by SC1, which is valuable for further research exploration. However, this research still needs to be verified by experiments. Future research will explore new drugs for treating coronary artery disease from these targets.
引用
收藏
页数:13
相关论文
共 100 条
[41]   The potentiation of myeloperoxidase activity by the glycosaminoglycan-dependent binding of myeloperoxidase to proteins of the extracellular matrix [J].
Kubala, Lukas ;
Kolarova, Hana ;
Vitecek, Jan ;
Kremserova, Silvie ;
Klinke, Anna ;
Lau, Denise ;
Chapman, Anna L. P. ;
Baldus, Stephan ;
Eiserich, Jason P. .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2013, 1830 (10) :4524-4536
[42]   The Role of Colchicine in Atherosclerotic Cardiovascular Disease [J].
Kurup, Rahul ;
Galougahi, Keyvan Karimi ;
Figtree, Gemma ;
Misra, Ashish ;
Patel, Sanjay .
HEART LUNG AND CIRCULATION, 2021, 30 (06) :795-806
[43]   Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? [J].
Kutter, D ;
Devaquet, P ;
Vanderstocken, G ;
Paulus, JM ;
Marchal, V ;
Gothot, A .
ACTA HAEMATOLOGICA, 2000, 104 (01) :10-15
[44]   2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J].
Lawton, Jennifer S. ;
Tamis-Holland, Jacqueline E. ;
Bangalore, Sripal ;
Bates, Eric R. ;
Beckie, Theresa M. ;
Bischoff, James M. ;
Bittl, John A. ;
Cohen, Mauricio G. ;
DiMaio, J. Michael ;
Don, Creighton W. ;
Fremes, Stephen E. ;
Gaudino, Mario F. ;
Goldberger, Zachary D. ;
Grant, Michael C. ;
Jaswal, Jang B. ;
Kurlansky, Paul A. ;
Mehran, Roxana ;
Metkus, Thomas S. Jr Jr ;
Nnacheta, Lorraine C. ;
Rao, Sunil, V ;
Sellke, Frank W. ;
Sharma, Garima ;
Yong, Celina M. ;
Zwischenberger, Brittany A. .
CIRCULATION, 2022, 145 (03) :E18-E114
[45]   Mitochondrial Dysfunction and Myocardial Ischemia-Reperfusion: Implications for Novel Therapies [J].
Lesnefsky, Edward J. ;
Chen, Qun ;
Tandler, Bernard ;
Hoppel, Charles L. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 :535-565
[46]   Marine Natural Products and Coronary Artery Disease [J].
Liang, Bo ;
Cai, Xin-Yi ;
Gu, Ning .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[47]   WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs [J].
Liao, Yuxing ;
Wang, Jing ;
Jaehnig, Eric J. ;
Shi, Zhiao ;
Zhang, Bing .
NUCLEIC ACIDS RESEARCH, 2019, 47 (W1) :W199-W205
[48]   MicroRNA-146a-3p/HDAC1/KLF5/IKBα signal axis modulates plaque formation of atherosclerosis mice [J].
Liu, Huajin ;
Wang, Hongwei ;
Ma, Jiangwei ;
Qiao, Zengyong ;
Zhang, Li ;
Ge, Guanghao .
LIFE SCIENCES, 2021, 284
[49]  
[刘钱 Liu Qian], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P1713
[50]   Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial [J].
Liuzzo, Giovanna ;
Patrono, Carlo .
EUROPEAN HEART JOURNAL, 2020, 41 (40) :3880-3881